Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo

Sphingosine 1-phosphate (S1P, 1 ) regulates vascular barrier and lymphoid development, as well as lymphocyte egress from lymphoid organs, by activating high-affinity S1P 1 receptors. We used reversible chemical probes (i) to gain mechanistic insights into S1P systems organization not accessible thro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature chemical biology 2006-08, Vol.2 (8), p.434-441
Hauptverfasser: Sanna, M Germana, Wang, Sheng-Kai, Gonzalez-Cabrera, Pedro J, Don, Anthony, Marsolais, David, Matheu, Melanie P, Wei, Sindy H, Parker, Ian, Jo, Euijung, Cheng, Wei-Chieh, Cahalan, Michael D, Wong, Chi-Huey, Rosen, Hugh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sphingosine 1-phosphate (S1P, 1 ) regulates vascular barrier and lymphoid development, as well as lymphocyte egress from lymphoid organs, by activating high-affinity S1P 1 receptors. We used reversible chemical probes (i) to gain mechanistic insights into S1P systems organization not accessible through genetic manipulations and (ii) to investigate their potential for therapeutic modulation. Vascular (but not airway) administration of the preferred R enantiomer of an in vivo –active chiral S1P 1 receptor antagonist induced loss of capillary integrity in mouse skin and lung. In contrast, the antagonist did not affect the number of constitutive blood lymphocytes. Instead, alteration of lymphocyte trafficking and phenotype required supraphysiological elevation of S1P 1 tone and was reversed by the antagonist. In vivo two-photon imaging of lymph nodes confirmed requirements for obligate agonism, and the data were consistent with the presence of a stromal barrier mechanism for gating lymphocyte egress. Thus, chemical modulation reveals differences in S1P-S1P 1 'set points' among tissues and highlights both mechanistic advantages (lymphocyte sequestration) and risks (pulmonary edema) of therapeutic intervention.
ISSN:1552-4450
1552-4469
DOI:10.1038/nchembio804